Document is current

Article History

Received: 10 May 2023

Accepted: 24 August 2023

First Online: 30 August 2023

Declarations

:

: The HCHS/SOL was approved by the institutional review boards (IRBs) at each field center, where all participants gave written informed consent in their preferred language (Spanish/English) to use their genetic and non-genetic data, and by the Non-Biomedical IRB at the University of North Carolina at Chapel Hill, to the HCHS/SOL Data Coordinating Center. All IRBs approving the study are: Non-Biomedical IRB at the University of North Carolina at Chapel Hill. Chapel Hill, NC; Einstein IRB at the Albert Einstein College of Medicine of Yeshiva University. Bronx, NY; IRB at Office for the Protection of Research Subjects (OPRS), University of Illinois at Chicago. Chicago, IL; Human Subject Research Office, University of Miami. Miami, FL; Institutional Review Board of San Diego State University, San Diego, CA. The study reported here was approved by the Mass General Brigham IRB under protocol #2019P000057. All methods and analyses of HCHS/SOL participants’ materials and data were carried out in accordance with human subject research guidelines and regulations.

: Richard B. Lipton, MD, has received support from the National Institutes of Health, and the US Food and Drug Administration. He serves as consultant for, advisory board member of, or has received honoraria or research support from AbbVie/Allergan, Amgen, Biohaven, Eli Lilly, GlaxoSmithKline, Lundbeck, Merck, Novartis, Teva, and Vector Psychometrics. He holds stock/options in Biohaven and Manistee.